



Consorzio Interuniversitario Nazionale per la Bio-Oncologia

presents

BREAST CANCER CONTROVERSIES

This house believes that ...

Chieti, June 27, 2016

Auditorium, G. D'Annunzio University

Directors: Ettore Cianchetti & Clara Natoli

09.45 Registration

10.15 Introduction and Authorities welcome

I session

Chairs: Corrado Ficorella, L'Aquila & Clara Natoli, Chieti

10.30 THBT Italian breast cancer screening guidelines should be updated

Marzia Muzi, Ortona

10.45 Discussion leader: Doralba Morrone, Florence

11.00 THBT neoadjuvant systemic therapy should be the standard of care for HER2+/triple negative operable breast cancer > 2cm

Valentina Guarneri, Padova

11.15 Discussion leader: Antonio Frassoldati, Ferrara

11.30 THBT selected HER2/++ FISH negative breast cancers should be considered as HER2/+++

Domenico Angelucci, Ortona

11.45 Discussion leader: Patrizia Querzoli, Ferrara

12.00 THBT axillary lymph node dissection should be avoided in patients with 1–2 macro-metastatic axillary lymph nodes

Ettore Cianchetti, Ortona

12.15 Discussion leader: Mario Taffurelli, Bologna

12.30 THBT hypo-fractionated irradiation and partial breast irradiation are recommended after breast conserving surgery

Domenico Genovesi, Chieti

12.45 Discussion leader: Lorenzo Livi, Florence

13.00 THBT chemoprevention and prophylactic surgery should be offered to healthy women carrying BRCA1/2 mutations

Laura Cortesi, Modena

13.15 Discussion leader: Francesco Fanfani, Chieti

13.30 *Light lunch*

II session

Chairs: Amedeo Pancotti, Teramo & Carlo Garufi, Pescara

14.30 THBT that fertility should be preserved in young women with early breast cancer

Gianmario Tiboni, Ortona

14.45 Discussion leader: Lucio Laudadio, Lanciano

15.00 THBT metronomic chemotherapy has an emerging role for early and advanced breast cancer treatment

Elisabetta Munzone, Milan

15.15 Discussion leader: Vito Lorusso, Bari

15.30 THBT that neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer women

Antonino Grassadonia, Chieti

15.45 Discussion leader: Silvana Leo, Lecce

16.00 Coffee break

16.15 THBT endocrine combination therapies are recommended for RE+ HER2- tumors

Katia Cannita, L'Aquila

16.30 Discussion leader: Serena Di Cosimo, Milan

III session –

Chairs: Antonio Nuzzo, Lanciano & Clara Natoli, Chieti

16.45 THBT taxanes and bevacizumab are the standard first line therapy for HER2- metastatic breast cancer

Luca Moscetti, Modena

17.00 Discussion leader: Giorgio Mustacchi, Trieste

17.15 THBT metastatic triple positive breast cancer needs different therapeutic strategies than HER2-enriched tumors

Patrizia Vici, Rome

17.30 Discussion leader: Andrea Michelotti, Pisa

17.45 Conclusions

Clara Natoli & Ettore Cianchetti

18.00 Questionario di valutazione dell'apprendimento

18.15 Chiusura dei lavori